טוען...
Uptake of new antidiabetic medicines in 11 European countries
BACKGROUND: Several new antidiabetic medicines (GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors) have been approved by the European Medicines Agency since 2006. The aim of this study was to evaluate the uptake of new antidiabetic medicines in European countries over a 10-year period...
שמור ב:
| הוצא לאור ב: | BMC Endocr Disord |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8235847/ https://ncbi.nlm.nih.gov/pubmed/34172020 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12902-021-00798-3 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|